Investigation announced for Long-Term Investors in shares of REGENXBIO Inc. (NASDAQ: RGNX) Long over potential Wrongdoing

An investigation was announced for current long-term investors in shares of REGENXBIO Inc. (NASDAQ: RGNX) concerning potential breaches of fiduciary duties by certain directors and officers of REGENXBIO Inc.

Investors who are current long term investors in REGENXBIO Inc. (NASDAQ: RGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: RGNX stocks follows a lawsuit filed against REGENXBIO Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: RGNX stocks, concerns whether certain REGENXBIO directors are liable in connection with the allegations made in that lawsuit.

Rockville, MD based REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. REGENXBIO Inc. (NASDAQ: RGNX) reported that its annual Total Revenue declined from $90.24 million in 2023 to $83.32 million in 2024, and that its Net Loss declined from $263.49 million in 2023 to $227.1 million in 2024.

On January 28, 2026, REGENXBIO Inc announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111. REGENXBIO Inc announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study.

Shares of REGENXBIO Inc. (NASDAQ: RGNX) declined from $35.73 per share on August 05, 2022, to as low as $7.61 per share on February 19, 2026.

According to that complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges that, the defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome, that the Defendants' statements included, among other things, REGENXBIO's positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study, and that the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study.

Those who purchased shares of REGENXBIO Inc. (NASDAQ: RGNX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.